Importance of on-time RotaTeq vaccination and long-term active surveillance

Pediatrics

Volumn 122, Issue 5, 2008, Pages 1153-1154

  Anderson, Evan J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE; LIVE VACCINE;

AGE; CONTROLLED STUDY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; INFANT; INTUSSUSCEPTION; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK; ROTAVIRUS; STATISTICAL ANALYSIS; VACCINATION; VIRUS INFECTION; WILD TYPE; IMMUNIZATION; NOTE; POSTMARKETING SURVEILLANCE; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INTUSSUSCEPTION; PRODUCT SURVEILLANCE, POSTMARKETING; ROTAVIRUS VACCINES; UNITED STATES; VACCINES, ATTENUATED;

EID: 58149166308     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-2152     Document Type: Letter

References (12)

1. Haber P, Patel M, Izurieta HS, et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics. 2008;121(6): 1206-1212
2. RotaTeq [prescribing information]. Whitehouse Station, NJ: Merck & Co; 2008
3. Rothman KJ, Young-Xu Y, Arellano F. Age dependence of the relation between reassortant rotavirus vaccine (RotaShield) and intussusception. J Infect Dis. 2006;193(6):898; author reply 898-899
4. Murphy BR, Morens DM, Simonsen L, Chanock RM, La Mon- tagne JR, Kapikian AZ. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial Conclusions. J Infect Dis. 2003;187(8):1301-1308
5. Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis. 2005;192(suppl 1):S36-S43
6. Davis RL, Kolczak M, Lewis E, et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology. 2005;16(3):336-341
7. Buettcher M, Baer G, Bonhoeffer J, Schaad UB, Heininger U. Three-year surveillance of intussusception in children in Switzerland. Pediatrics. 2007;120(3):473-480
8. Kombo LA, Gerber MA, Pickering LK, Atreya CD, Breiman RF. Intussusception, infection, and immunization: summary of a workshop on rotavirus. Pediatrics. 2001;108(2). Available at: www.pediatrics.org/cgi/ content/full/108/2/e37
9. Robinson CG, Hernanz-Schulman M, Zhu Y, Griffin MR, Gru-ber W, Edwards KM. Evaluation of anatomic changes in young children with natural rotavirus infection: is intussusception biologically plausible? J Infect Dis. 2004;189(8):1382-1387
10. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23-33
11. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11-22
12. Rotarix [summary of product characteristics]. Rixensart, Belgium: GlaxoSmithKline Biologicals; 2008